Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are probably the most maturely produced TPD approaches. During this critique, we focus on each preclinical experiments and medical trials to deliver a comprehensive summary of the safety and scientific efficiency of PROTACs and MGDs in hematologic malignancies over the pas